English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

. Epidermal growth factor receptor inhibitors (EGFRI) are commonly used in the treatment of solid tumors. Cutaneous side effects occur in 80% of patients and are the most frequent adverse events. However, cicatricial alopecia is a rarely described side effect of EGFRI.  Objective . To present cutaneous toxicities in a patient treated with erlotinib and underscore cicatricial alopecia, rarely described in the literature.  Case report.   We present a 63-year-old woman diagnosed with non-small cell lung cancer and treated with erlotinib, who developed extensive papulo-pustular eruption with severe involvement of the scalp and cicatricial alopecia. Other adverse events included trichomegaly, paronychia, granuloma pyogenicum-like lesions, dryness of the skin and pruritus.  Conclusions . Cicatricial alopecia in the presented patient may be a result of delayed introduction of dermatological treatment. Therefore, all dermatologists should be aware of treatment modalities of EGFRI-induced toxicities

Severe cicatricial alopecia as a rare cutaneous side effect due to erlotinib – case report